Literature DB >> 31859917

ADJUVANT CHEMORADIOTHERAPY AFTER SUBTOTAL OR TOTAL GASTRECTOMY AND D2 LIMPHADENECTOMY INCREASES SURVIVAL IN ADVANCED GASTRIC CANCER?

Nelson Adami Andreollo1, Eric Drizlionoks1, Valdir Tercioti-Junior1, João de Souza Coelho-Neto1, José Antonio Possato Ferrer1, José Barreto Campello Carvalheira2, Luiz Roberto Lopes1.   

Abstract

BACKGROUND: The treatment of advanced gastric cancer with curative intent is essentially surgical and chemoradiotherapy is indicated as neo or adjuvant to control the disease and prolong survival. AIM: To assess the survival of patients undergoing subtotal or total gastrectomy with D2 lymphadenectomy followed by adjuvant chemoradiotherapy.
METHODS: Were retrospectively analyzed 87 gastrectomized patients with advanced gastric adenocarcinoma, considered stages IB to IIIC and submitted to adjuvant chemoradiotherapy (protocol INT 0116). Tumors of the esophagogastric junction, with peritoneal implants, distant metastases, and those that had a compromised surgical margin or early death after surgery were excluded. They were separated according to the extention of the gastrectomy and analyzed for tumor site and histopathology, lymph node invasion, staging, morbidity and survival.
RESULTS: The total number of patients who successfully completed the adjuvant treatment was 45 (51.7%). Those who started treatment and discontinued due to toxicity, tumor-related worsening, or loss of follow-up were 10 (11.5%) and reported as incomplete adjuvant. The number of patients who refused or did not start adjuvant treatment was 33 (48.3%). Subtotal gastrectomy was indicated in 60 (68.9%) and total in 27 (31.1%) and this had a shorter survival. The mean resected lymph nodes was 30.8. Staging and number of lymph nodes affected were predictors of worse survival and the more advanced the tumor. Patients undergoing adjuvant therapy with complete chemoradiotherapy showed a longer survival when compared to those who did it incompletely or underwent exclusive surgery. On the other hand, comparing the T4b (IIIB + IIIC) staging patients who had complete adjuvance with those who underwent the exclusive operation or who did not complete the adjuvant, there was a significant difference in survival.
CONCLUSION: Adjuvant chemoradiotherapy presents survival gain for T4b patients undergoing surgical treatment with curative intent.

Entities:  

Mesh:

Year:  2019        PMID: 31859917      PMCID: PMC6918727          DOI: 10.1590/0102-672020190001e1464

Source DB:  PubMed          Journal:  Arq Bras Cir Dig        ISSN: 0102-6720


  36 in total

1.  Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.

Authors:  Mitsuru Sasako; Shinichi Sakuramoto; Hitoshi Katai; Taira Kinoshita; Hiroshi Furukawa; Toshiharu Yamaguchi; Atsushi Nashimoto; Masashi Fujii; Toshifusa Nakajima; Yasuo Ohashi
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

2.  Japanese classification of gastric carcinoma: 3rd English edition.

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

3.  Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

Authors:  Marc Ychou; Valérie Boige; Jean-Pierre Pignon; Thierry Conroy; Olivier Bouché; Gilles Lebreton; Muriel Ducourtieux; Laurent Bedenne; Jean-Michel Fabre; Bernard Saint-Aubert; Jean Genève; Philippe Lasser; Philippe Rougier
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

Review 4.  Adjuvant therapy for gastric cancer: what have we learned since INT0116?

Authors:  Alexandre A Jácome; Ajith K Sankarankutty; José Sebastião dos Santos
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

5.  T4b gastric carcinoma: 12 years of experience at an University Hospital.

Authors:  Bernard Costa Favacho; Carleno da Silva Costa; Thamer Costa Magalhães; Paulo Pimentel de Assumpção; Geraldo Ishak
Journal:  Arq Bras Cir Dig       Date:  2013 Nov-Dec

6.  Four hundred consecutive total gastrectomies for gastric cancer: a single-institution experience.

Authors:  Fabio Pacelli; Valerio Papa; Fausto Rosa; Antonio Pio Tortorelli; Alejandro Martin Sanchez; Marcello Covino; Maurizio Bossola; Giovanni Battista Doglietto
Journal:  Arch Surg       Date:  2008-08

7.  DETECTION OF OCCULT LYMPH NODE TUMOR CELLS IN NODE-NEGATIVE GASTRIC CANCER PATIENTS.

Authors:  Marina Alessandra Pereira; Marcus Fernando Kodama Pertille Ramos; Andre Roncon Dias; Osmar Kenji Yagi; Sheila Friedrich Faraj; Bruno Zilberstein; Ivan Cecconello; Evandro Sobroza de Mello; Ulysses Ribeiro
Journal:  Arq Bras Cir Dig       Date:  2017 Jan-Mar

Review 8.  Optimal management of resected gastric cancer.

Authors:  Riccardo Giampieri; Michela Del Prete; Luca Cantini; Maria Giuditta Baleani; Alessandro Bittoni; Elena Maccaroni; Rossana Berardi
Journal:  Cancer Manag Res       Date:  2018-06-21       Impact factor: 3.989

9.  CONVERSION THERAPY FOR GASTRIC CANCER: EXPANDING THE TREATMENT POSSIBILITIES.

Authors:  Marcus Fernando Kodama Pertille Ramos; Marina Alessandra Pereira; Amir Zeide Charruf; André Roncon Dias; Tiago Biachi de Castria; Leandro Cardoso Barchi; Ulysses Ribeiro-Júnior; Bruno Zilberstein; Ivan Cecconello
Journal:  Arq Bras Cir Dig       Date:  2019-04-29

Review 10.  Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine.

Authors:  Yoon Young Choi; Sung Hoon Noh; Jae-Ho Cheong
Journal:  Yonsei Med J       Date:  2015-09       Impact factor: 2.759

View more
  1 in total

1.  GASTRECTOMY IN OCTOGENARIANS WITH GASTRIC CANCER: IS IT FEASIBLE?

Authors:  Francisco Diogo Almeida Silva; Marina Alessandra Pereira; Marcus Fernando Kodama Pertille Ramos; Ulysses Ribeiro-Junior; Bruno Zilberstein; Ivan Cecconello; Andre Roncon Dias
Journal:  Arq Bras Cir Dig       Date:  2021-01-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.